Jump to content

MDAT

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Rollie (talk | contribs) at 11:38, 2 June 2010 (Undid revision 365621060 by 82.24.103.156 (talk)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

MDAT
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-7-amine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H13NO2
Molar mass191.223 g/mol g·mol−1
3D model (JSmol)
  • C3Cc1cc2OCOc2cc1CC3N

6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols.[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.[1] Hence, MDAT is a non-neurotoxic, putative entactogen in humans.

See Also

References

  1. ^ a b Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry. 33 (2): 703–10. PMID 1967651. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)


Retrieved from "https://en.wikipedia.org/w/index.php?title=MDAT&oldid=365622284"